Funded Biotechnology Startups in Cambridge
The 50 most recent biotechnology funding rounds across Cambridge, Massachusetts and Cambridge, Cambridgeshire span October 2024 through November 2025.
The 50 most recent biotechnology funding rounds across Cambridge, Massachusetts and Cambridge, Cambridgeshire span October 2024 through November 2025. Cambridge, MA accounts for 37 of the 50 companies, with the largest individual rounds — Scholar Rock at $300M (October 2024), Odyssey Therapeutics at $213M Series D (September 2025), and Aviceda Therapeutics at $208M Series C (January 2025) — all US-based. Cambridge, UK contributes 13 companies, headlined by Artios Pharma's $115M Series D (November 2025) and CellCentric's $120M Series C (May 2025).
Round-stage labels skew heavily toward "Series Unknown" in both geographies. Series B is the most represented named stage, with seven closings including AIRNA ($155M, April 2025), Strand Therapeutics ($153M, August 2025), and ARTBIO ($132M, July 2025). A handful of early-stage rounds — a $2M Seed from OutSee (Cambridge, UK) and a $10M Pre-Seed from Sortera Bio — sit in the same window as nine-figure raises, reflecting the full spectrum of biotechnology capital deployment across both cities.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these 50 companies?
Scholar Rock leads at $300M (October 2024), followed by Odyssey Therapeutics at $213M Series D (September 2025) and Aviceda Therapeutics at $208M Series C (January 2025). KalVista Pharmaceuticals ($179M, November 2024) and Vor Biopharma ($175M, June 2025) round out the top five among the rounds shown.
How is the Cambridge, MA versus Cambridge, UK split across these 50 companies?
Of the 50 companies shown, 37 are based in Cambridge, Massachusetts and 13 in Cambridge, Cambridgeshire. Cambridge, MA generates the largest individual rounds on average, though Cambridge, UK contributes competitive growth-stage deals including CellCentric's $120M Series C (May 2025) and Artios Pharma's $115M Series D (November 2025).
Which round stages appear most frequently?
"Series Unknown" — rounds where stage was not publicly disclosed — is the most common label across both cities. Among named stages, Series B appears seven times, including AIRNA ($155M, April 2025), Strand Therapeutics ($153M, August 2025), and ARTBIO ($132M, July 2025). Series A and Series C each appear four times.
Are there early-stage rounds included in this listing?
Yes. OutSee and Surgicure Technologies each closed $2M Seed rounds, TRIMTECH Therapeutics raised a $31M Seed in March 2025, and Sortera Bio completed a $10M Pre-Seed in June 2025. OutSee and Sortera Bio are both Cambridge, Cambridgeshire companies; the others are Cambridge, MA.
What date range do these 50 rounds cover?
The earliest round shown is Judo Bio's Series A from October 7, 2024; the most recent are Artios Pharma and Solarea Bio, both closing November 20, 2025. The dataset covers approximately 13 months of disclosed activity across both Cambridges.
Are any disclosed round sizes notably small relative to the rest of the dataset?
Two companies reported sub-$200K rounds: Astrocyte Pharmaceuticals at $110K (December 2024) and Shape Biopharmaceuticals at $170K (November 2024), both in Cambridge, MA. Monument Therapeutics (Cambridge, UK) and Dynocardia (Cambridge, MA) each reported $1M rounds in Q4 2024, suggesting bridge or insider capital rather than institutional raises.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.